The Causal Effect of Vitamin D Binding Protein (DBP) Levels on Calcemic and Cardiometabolic Diseases: A Mendelian Randomization Study

English version České info

Background:
Observational studies have shown that vitamin D binding protein (DBP) levels, a key determinant of 25-hydroxy-vitamin D (25OHD) levels, and 25OHD levels themselves both associate with risk of disease. If 25OHD levels have a causal influence on disease, and DBP lies in this causal pathway, then DBP levels should likewise be causally associated with disease. We undertook a Mendelian randomization study to determine whether DBP levels have causal effects on common calcemic and cardiometabolic disease.

Methods and Findings:
We measured DBP and 25OHD levels in 2,254 individuals, followed for up to 10 y, in the Canadian Multicentre Osteoporosis Study (CaMos). Using the single nucleotide polymorphism rs2282679 as an instrumental variable, we applied Mendelian randomization methods to determine the causal effect of DBP on calcemic (osteoporosis and hyperparathyroidism) and cardiometabolic diseases (hypertension, type 2 diabetes, coronary artery disease, and stroke) and related traits, first in CaMos and then in large-scale genome-wide association study consortia. The effect allele was associated with an age- and sex-adjusted decrease in DBP level of 27.4 mg/l (95% CI 24.7, 30.0; n = 2,254). DBP had a strong observational and causal association with 25OHD levels (p = 3.2×10⁻¹⁹). While DBP levels were observationally associated with calcium and body mass index (BMI), these associations were not supported by causal analyses. Despite well-powered sample sizes from consortia, there were no associations of rs2282679 with any other traits and diseases: fasting glucose (0.00 mmol/l [95% CI −0.01, 0.01]; p = 1.00; n = 46,186); fasting insulin (0.01 pmol/l [95% CI −0.00, 0.01,]; p = 0.22; n = 46,186); BMI (0.00 kg/m² [95% CI −0.01, 0.01]; p = 0.80; n = 127,587); bone mineral density (0.01 g/cm² [95% CI −0.01, 0.03]; p = 0.36; n = 32,961); mean arterial pressure (−0.06 mm Hg [95% CI −0.19, 0.07]); p = 0.36; n = 28,775); ischemic stroke (odds ratio [OR] = 1.00 [95% CI 0.97, 1.04]; p = 0.92; n = 12,389/62,004 cases/controls); coronary artery disease (OR = 1.02 [95% CI 0.99, 1.05]; p = 0.31; n = 22,233/64,762); or type 2 diabetes (OR = 1.01 [95% CI 0.97, 1.05]; p = 0.76; n = 9,580/53,810).

Conclusions:
DBP has no demonstrable causal effect on any of the diseases or traits investigated here, except 25OHD levels. It remains to be determined whether 25OHD has a causal effect on these outcomes independent of DBP.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: The Causal Effect of Vitamin D Binding Protein (DBP) Levels on Calcemic and Cardiometabolic Diseases: A Mendelian Randomization Study. PLoS Med 11(10): e32767. doi:10.1371/journal.pmed.1001751
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001751

Souhrn

Zdroje

1. HolickMF, BinkleyNC, Bischoff-FerrariHA, GordonCM, HanleyDA, et al. (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96: 1911–1930.

2. HolickMF (2007) Vitamin D deficiency. N Engl J Med 357: 266–281.

3. ArtazaJN, MehrotraR, NorrisKC (2009) Vitamin D and the cardiovascular system. Clin J Am Soc Nephrol 4: 1515–1522.

4. GiallauriaF, MilaneschiY, TanakaT, MaggioM, CanepaM, et al. (2012) Arterial stiffness and vitamin D levels: the Baltimore longitudinal study of aging. J Clin Endocrinol Metab 97: 3717–3723.

5. LaiH, FishmanEK, GerstenblithG, BrinkerJA, TongW, et al. (2012) Vitamin D deficiency is associated with significant coronary stenoses in asymptomatic African American chronic cocaine users. Int J Cardiol 158: 211–216.

6. TakiishiT, GysemansC, BouillonR, MathieuC (2010) Vitamin D and diabetes. Endocrinol Metab Clin North Am 39: 419–446.

7. ThrailkillKM, JoCH, CockrellGE, MoreauCS, FowlkesJL (2011) Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency? J Clin Endocrinol Metab 96: 142–149.

8. HatseS, LambrechtsD, VerstuyfA, SmeetsA, BrouwersB, et al. (2012) Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis 33: 1319–1326.

9. MondulAM, WeinsteinSJ, VirtamoJ, AlbanesD (2012) Influence of vitamin D binding protein on the association between circulating vitamin D and risk of bladder cancer. Br J Cancer 107: 1589–1594.

10. TheodoratouE, PalmerT, ZgagaL, FarringtonSM, McKeigueP, et al. (2012) Instrumental variable estimation of the causal effect of plasma 25-hydroxy-vitamin D on colorectal cancer risk: a mendelian randomization analysis. PLoS ONE 7: e37662.

11. StokesCS, VolmerDA, GrunhageF, LammertF (2013) Vitamin D in chronic liver disease. Liver Int 33: 338–352.

12. MakG, HananiaNA (2011) Vitamin D and asthma. Curr Opin Pulm Med 17: 1–5.

13. ChalmersJD, McHughBJ, DochertyC, GovanJR, HillAT (2013) Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 68: 39–47.

14. MaxwellCS, CarboneET, WoodRJ (2012) Better newborn vitamin D status lowers RSV-associated bronchiolitis in infants. Nutr Rev 70: 548–552.

15. MarquesCD, DantasAT, FragosoTS, DuarteAL (2010) The importance of vitamin D levels in autoimmune diseases. Rev Bras Reumatol 50: 67–80.

16. BenrashidM, MoyersK, MohtyM, SavaniBN (2012) Vitamin D deficiency, autoimmunity, and graft-versus-host-disease risk: implication for preventive therapy. Exp Hematol 40: 263–267.

17. LevinAD, WadheraV, LeachST, WoodheadHJ, LembergDA, et al. (2011) Vitamin D deficiency in children with inflammatory bowel disease. Dig Dis Sci 56: 830–836.

18. ErtenS, AltunogluA, CeylanGG, MarasY, KocaC, et al. (2012) Low plasma vitamin D levels in patients with familial Mediterranean fever. Rheumatol Int 32: 3845–3849.

19. Fernandes de AbreuDA, LandelV, FeronF (2011) Seasonal, gestational and postnatal influences on multiple sclerosis: the beneficial role of a vitamin D supplementation during early life. J Neurol Sci 311: 64–68.

20. HiraniV (2012) Vitamin D status and pain: analysis from the Health Survey for England among English adults aged 65 years and over. Br J Nutr 107: 1080–1084.

21. HiraniV, TullK, AliA, MindellJ (2010) Urgent action needed to improve vitamin D status among older people in England!. Age Ageing 39: 62–68.

22. VerbovenC, RabijnsA, De MaeyerM, Van BaelenH, BouillonR, et al. (2002) A structural basis for the unique binding features of the human vitamin D-binding protein. Nat Struct Biol 9: 131–136.

23. SafadiFF, ThorntonP, MagieraH, HollisBW, GentileM, et al. (1999) Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 103: 239–251.

24. BikleDD, SiiteriPK, RyzenE, HaddadJG (1985) Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels. J Clin Endocrinol Metab 61: 969–975.

25. NykjaerA, DragunD, WaltherD, VorumH, JacobsenC, et al. (1999) An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96: 507–515.

26. WangTJ, ZhangF, RichardsJB, KestenbaumB, van MeursJB, et al. (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376: 180–188.

27. AhnJ, YuK, Stolzenberg-SolomonR, SimonKC, McCulloughML, et al. (2010) Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 19: 2739–2745.

28. LuL, ShengH, LiH, GanW, LiuC, et al. (2012) Associations between common variants in GC and DHCR7/NADSYN1 and vitamin D concentration in Chinese Hans. Hum Genet 131: 505–512.

29. MuindiJR, AdjeiAA, WuZR, OlsonI, HuangH, et al. (2013) Serum vitamin D metabolites in colorectal cancer patients receiving cholecalciferol supplementation: correlation with polymorphisms in the vitamin D genes. Horm Cancer 4: 242–250.

30. AdamsJS, ChenH, ChunR, RenS, WuS, et al. (2007) Substrate and enzyme trafficking as a means of regulating 1,25-dihydroxyvitamin D synthesis and action: the human innate immune response. J Bone Miner Res 22 (Suppl 2) V20–V24.

31. ChunRF (2012) New perspectives on the vitamin D binding protein. Cell Biochem Funct 30: 445–456.

32. GommePT, BertoliniJ (2004) Therapeutic potential of vitamin D-binding protein. Trends Biotechnol 22: 340–345.

33. Lopez-FarreAJ, Mateos-CaceresPJ, SacristanD, AzconaL, BernardoE, et al. (2007) Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients: a proteomic study. J Proteome Res 6: 2481–2487.

34. GibsonDS, NewellK, EvansAN, FinneganS, ManningG, et al. (2012) Vitamin D binding protein isoforms as candidate predictors of disease extension in childhood arthritis. J Proteomics 75: 5479–5492.

35. BlantonD, HanZ, BierschenkL, Linga-ReddyMV, WangH, et al. (2011) Reduced serum vitamin D-binding protein levels are associated with type 1 diabetes. Diabetes 60: 2566–2570.

36. RocchiccioliS, AndreassiMG, CecchettiniA, CarpeggianiC, L'AbbateA, et al. (2012) Correlation between vitamin D binding protein expression and angiographic-proven coronary artery disease. Coron Artery Dis 23: 426–431.

37. GasparriC, CurcioA, TorellaD, GaspariM, CeliV, et al. (2010) Proteomics reveals high levels of vitamin D binding protein in myocardial infarction. Front Biosci (Elite Ed) 2: 796–804.

38. BaierLJ, DobberfuhlAM, PratleyRE, HansonRL, BogardusC (1998) Variations in the vitamin D-binding protein (Gc locus) are associated with oral glucose tolerance in nondiabetic Pima Indians. J Clin Endocrinol Metab 83: 2993–2996.

39. SzathmaryEJ (1987) The effect of Gc genotype on fasting insulin level in Dogrib Indians. Hum Genet 75: 368–372.

40. FangY, van MeursJB, ArpP, van LeeuwenJP, HofmanA, et al. (2009) Vitamin D binding protein genotype and osteoporosis. Calcif Tissue Int 85: 85–93.

41. AbbasS, LinseisenJ, SlangerT, KroppS, MutschelknaussEJ, et al. (2008) The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiol Biomarkers Prev 17: 1339–1343.

42. CaldwellJD, JirikowskiGF (2013) Sex hormone binding globulin and corticosteroid binding globulin as major effectors of steroid action. Steroids 81: 13–16.

43. LawlorDA, HarbordRM, SterneJA, TimpsonN, Davey SmithG (2008) Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 27: 1133–1163.

44. JacksonSA, TenenhouseA, RobertsonL (2000) Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int 11: 680–687.

45. TraylorM, FarrallM, HollidayEG, SudlowC, HopewellJC, et al. (2012) Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol 11: 951–962.

46. EstradaK, StyrkarsdottirU, EvangelouE, HsuYH, DuncanEL, et al. (2012) Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 44: 491–501.

47. MorrisAP, VoightBF, TeslovichTM, FerreiraT, SegreAV, et al. (2012) Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 44: 981–990.

48. International Consortium for Blood Pressure Genome-Wide Association Studies (2011) EhretGB, MunroePB, RiceKM, BochudM, et al. (2011) Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478: 103–109.

49. DupuisJ, LangenbergC, ProkopenkoI, SaxenaR, SoranzoN, et al. (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42: 105–116.

50. YangJ, LoosRJ, PowellJE, MedlandSE, SpeliotesEK, et al. (2012) FTO genotype is associated with phenotypic variability of body mass index. Nature 490: 267–272.

51. SchunkertH, KonigIR, KathiresanS, ReillyMP, AssimesTL, et al. (2011) Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 43: 333–338.

52. FanB, LuY, GenantH, FuerstT, ShepherdJ (2010) Does standardized BMD still remove differences between Hologic and GE-Lunar state-of-the-art DXA systems? Osteoporos Int 21: 1227–1236.

53. LuY, FuerstT, HuiS, GenantHK (2001) Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int 12: 438–444.

54. BergerC, GoltzmanD, LangsetmoL, JosephL, JacksonS, et al. (2010) Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res 25: 1948–1957.

55. BergerC, Greene-FinestoneLS, LangsetmoL, KreigerN, JosephL, et al. (2012) Temporal trends and determinants of longitudinal change in 25-hydroxyvitamin D and parathyroid hormone levels. J Bone Miner Res 27: 1381–1389.

56. LeveyAS, StevensLA, SchmidCH, ZhangYL, CastroAF3rd, et al. (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612.

57. BaumCF, SchafferME, StillmanS (2003) Instrumental variables and GMM: estimation and testing. Stata J 3: 1–31.

58. NordestgaardBG, PalmerTM, BennM, ZachoJ, Tybjaerg-HansenA, et al. (2012) The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med 9: e1001212.

59. BrionMJ, ShakhbazovK, VisscherPM (2013) Calculating statistical power in Mendelian randomization studies. Int J Epidemiol 42: 1497–1501.

60. Greene-FinestoneLS, BergerC, de GrohM, HanleyDA, HidiroglouN, et al. (2011) 25-hydroxyvitamin D in Canadian adults: biological, environmental, and behavioral correlates. Osteoporos Int 22: 1389–1399.

61. DastaniZ, BergerC, LangsetmoL, FuL, WongBY, et al. (2014) In healthy adults, biological activity of vitamin D, as assessed by serum PTH, is largely independent of DBP concentrations. J Bone Miner Res 29: 494–499.

62. PoweCE, EvansMK, WengerJ, ZondermanAB, BergAH, et al. (2013) Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 369: 1991–2000.

63. SmithGD, EbrahimS (2003) ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1–22.

64. BrunnerEJ, KivimakiM, WitteDR, LawlorDA, Davey SmithG, et al. (2008) Inflammation, insulin resistance, and diabetes—Mendelian randomization using CRP haplotypes points upstream. PLoS Med 5: e155.

65. HartmanJL4th, GarvikB, HartwellL (2001) Principles for the buffering of genetic variation. Science 291: 1001–1004.

66. ColhounHM, McKeiguePM, Davey SmithG (2003) Problems of reporting genetic associations with complex outcomes. Lancet 361: 865–872.

67. VimaleswaranKS, CavadinoA, BerryDJ (2014) LifeLines Cohort Study Investigators (2014) JordeR, et al. (2014) Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study. Lancet Diabetes Endocrinol 2: 719–729.

68. VimaleswaranKS, BerryDJ, LuC, TikkanenE, PilzS, et al. (2013) Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med 10: e1001383.

69. ReidIR, BollandMJ, GreyA (2014) Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 383: 146–155.

70. PludowskiP, GrantWB, BhattoaHP, BayerM, PovoroznyukV, et al. (2014) Vitamin D status in central Europe. Int J Endocrinol 2014: 589587.

71. LipsP, HoskingD, LippunerK, NorquistJM, WehrenL, et al. (2006) The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med 260: 245–254.